Materials and Methods chemicals and reagents
All organic solvents were HPLC grade and were obtained from Fisher. MilliQ-grade water was produced by a Millipore system (Millipore). Hydroxypropyl ␤-cyclodextrin (Trappsol ® ) was obtained from Cyclodextrin Technologies Development, Inc.; Trasylol ® from Bayer; and human C-peptide standard (84/510) from the National Institutes for Biological Standards and Control (10 ) .
preparation of c-peptide tracer and calibrators
Human-sequence isotope-labeled C-peptides with relative molecular masses (M r ) of 3038 [Mϩ18] and 3050 [Mϩ30] were synthesized via incorporation of multiple fluorenylmethyloxycarbonyl-labeled amino acids containing either 13 C or 15 N labels on an ABI 433A Peptide Synthesizer by solid-phase chemistry. Peptides were purified by preparative reversed-phase (RP) HPLC. Synthetic C-peptides ([Mϩ18] and [Mϩ30]) for infusion or use as internal standard (IS) were quantified by nitrogen and amino acid analysis. The C-peptide IS ([Mϩ30] ; M r 3050) was used to prepare stock solutions (9.8 g/L) in 50 mmol/L phosphate buffer (pH 7) containing 2 g/L human serum albumin, 250 kilounits/L Trasylol, and 6 g/L m-cresol, and stored at Ϫ20°C until thawed for use. Concentrations of stock solutions of M r 3050 IS were verified against the WHO human C-peptide reference standard 84/510 (10 ) by both specific C-peptide RIA (Linco) and by LC/MS with good agreement (within 5%).
ms quantification of c-peptide
To generate a calibration curve, we dissolved C-peptides in dilution buffer [5 g/L human serum albumin, 5 g/L hydroxypropyl ␤-cyclodextrin, 15 mmol/L sodium EDTA, 0.8 mol/L guanidine hydrochloride (GuHCl), 25 mmol/L potassium phosphate (pH 8.0), 25 mL/L acetonitrile, 1.5 mL/L trifluoroacetic acid (TFA)] and injected 50 L directly on the column, representing 2-8000 pg of C-peptide. For the IDA calibration curve, we added 0 -150 L of 9.8 g/L M r 3050 IS to 300 L of a quality-control human plasma stock (containing 500 kilounits/L Trasylol) and brought the sample volume up to 450 L with dilution buffer. Samples underwent solid-phase extraction (SPE) as described below. We injected 50 L of the resolubilized lyophilisate, representing ϳ60 L of plasma and ϳ400 pg of endogenous C-peptide on column. The C-peptide concentration in the quality-control stock was calculated as the mean of 20 consecutive measurements calibrated against our [Mϩ30] IS, the concentration of which had been determined by nitrogen analysis and RIA. This C-peptide stock became our standard against which measurement errors were calculated.
isotope-dilution assay
IDAs are based on quantitative detection of an analyte signal by MS relative to a heavy-isotope-labeled IS that is added at known concentration (6, 7, 17 ) . The analyte and IS are of identical amino acid composition and exhibit identical physiochemical properties except that they differ in their m/z ratio (e.g., 1007.7 vs 1017.7 for C-peptide and the [Mϩ30] IS). Because the signal strength is linear for both analyte and standard, the plasma concentration can be calculated directly from the ratio of the signals.
human plasma samples for c-peptide
All human studies were approved by the Albert Einstein College of Medicine Committee on Clinical Investigations (Institutional Review Board). All participants provided written informed consent before participation. We obtained samples from healthy persons participating in studies monitoring the effect of nutrient stimulation on insulin secretion and C-peptide output, and as such samples were obtained under basal and stimulated conditions. For analysis in independent protocols, some participants received an infusion of 15 N-labeled [Mϩ18] C-peptide during our study. Results of in vivo 15 N Cpeptide pharmacokinetics will be reported separately. Briefly, participants received an intravenous bolus containing 6.5 g/m 2 glucose, followed by a variable infusion of 18.2% glucose to clamp the plasma glucose concentration at 1.8 g/L. Additional blood samples were collected into EDTA-containing tubes supplemented with Trasylol (500 kilounits/L) and placed on ice; after centrifugation plasma was stored at Ϫ80°C before LC/MS analysis.
immunoassays Plasma C-peptide was quantified by RIA for human C-peptide according to the manufacturer's instructions (product no. HCP-20K; Linco). Both intra-and interassay CVs for this assay are reported to be Ͻ5%, and the standards are calibrated against the WHO C-peptide reference standard 85/510 (10 ).
sample preparation: spe procedure Method. C 8 SPE cartridges (Sep-Pak Plus; Waters) were activated by washing with 4 mL of absolute methanol and then washed with 5 mL of 500 mL/L acetonitrile. After 0.3 mL of plasma was enriched with 0.1 mL of IS (9.8 g/L [Mϩ30] C-peptide) and 100 L of 50 mL/L acetonitrile, it was vortex-mixed and loaded with a P1000 pipette on Sep-Pak Plus C 8 cartridges. We performed the sample loading and the first wash step with a 1-mL adjustable volume pipette (blue tip) through the outlet of the SPE cartridge (opposite direction to conventional sample load-ing). Cartridges were washed with 1 mL of 500 mL/L acetonitrile, followed by 3 mL of 200 mL/L acetonitrile containing 1 mL/L TFA. C-Peptide was then eluted with 3.6 mL of 350 mL/L acetonitrile in 25 mmol/L potassium phosphate (pH 8) into 4-mL NUNC TM CryoTube vials. The C-peptide-containing fraction was collected, freezedried, and stored at 4°C until LC/MS analysis.
Before LC/MS analysis, we solubilized the freezedried extracts with 75 L of 8 mol/L GuHCl for 20 min, then added 0.15 mL of 50 mL/L acetonitrile containing 3 mL/L TFA. Samples were filtered through a 0.45 m Ultrafree-MC centrifugation filter (Millipore) and transferred into autosampler vials with 400-L flat-bottomed inserts containing an additional 40 L of 8 mol/L GuHCl. The autosampler injected 50 L of sample into the firstdimension column. All samples were analyzed in duplicate. The total sample volume was sufficient for 4 injections.
Calculation of C-peptide recovery after SPE. We added 100 L of 9.8 g/L IS ([Mϩ30]) to 0.3 mL of human plasma. Samples (n ϭ 5) were prepared according to the SPE procedure described above. To recovery control samples, we added 0.1 mL of 9.8 g/L IS ([Mϩ30]) directly into 3.5 mL of SPE elution buffer (acetonitrile-phosphate buffer), followed by drying. All samples were reconstituted and analyzed by LC/MS in duplicate. Recovery was calculated (as a percentage) as the ratio of the mean sample area to mean control area.
instruments
We used an 1100 series 2D LC system (Agilent), equipped with binary and capillary pumps and a column compartment with 2-position Rheodyne thermostabilized valves. LC/MS analysis was performed on SCIEX API 365 and API 4000 triple quadrupole mass spectrometers (Applied Biosystems) equipped with a Turboionspray source. The LC experimental setup is shown in Fig. 1 .
lc/ms operating conditions
We performed first-dimension chromatography with a complex gradient elution on a Jupiter C 5 column [bead size, 5-m ; pore size, 300 Å; 100 ϫ 2 mm (i.d.)] from Phenomenex equipped with a 4 ϫ 2 mm (i.d.) guard column ( Table 1 ). The first-dimension separation was by mobile phases composed of 1 mL/L TFA in water (mobile phase A) and acetonitrile (mobile phase B). The seconddimension separation involved a complex gradient on a Pursuit C 18 column [bead size, 3-m; pore size, 180 Å; 50 ϫ 2 mm (i.d.)] from Varian. The second-dimension separation mobile phases consisted of 4 mL/L formic acid, 10 mL/L isopropyl alcohol, and 20 mL/L methanol in water (mobile phase A) and acetonitrile (mobile phase B). Both columns and a Rheodyne switching valve were operated at 40°C.
We used the switching valve to transfer samples loaded on the first-dimension column and the peak heart cut of the analyte to the second-dimension column and performed MS analysis of the analyte on the seconddimension column while the first column continued regeneration and equilibration ( Table 1 ). The total method time was 16 min. Additional details are available (18 ) .
ms detection and quantification
Because of the low fragmentation efficiency of the analyte, we analyzed C-peptides by electrospray MS in positive ionization with selective ion monitoring. The molecular ion for C-peptide was monitored in the 3ϩ state at m/z 1007.7 for native C-peptide, 1013. (A), C-peptide is trapped on the first column while the second column is regenerated with flow going to waste. (B), the effluent corresponding to the heart of the C-peptide peak on the first column is sent to the second column and trapped by simultaneous infusion of low-organic buffer (3:5 ratio). While the C-peptide is being eluted from the second column by gradient elution and sent to the mass spectrometer, the first column is regenerated. The effluent from column 2 is directed toward waste until near to the elution time of C-peptide, when the flow is directed to the mass spectrometer. This arrangement increases column lifetime and reduces mass spectrometer contamination. Total method time is 16 min and is not increased by use of 2 dimensions. Details on the flow rates and column switching are given in Table 1 
Results

lc/ms development
Our LC/MS method used 2 generic high-resolution silicabased RP columns with different pore sizes and different chemistry (Fig. 1) . The sample prepurified by C 8 SPE was desalted and purified on the first-dimension column by TFA-containing mobile phases. The peak of interest was transferred by a Rheodyne column-switching valve into the second-dimension RP/MS column. This column was simultaneously preflushed, via a T-shaped mixing connector, with low-organic mobile phase to improve Cpeptide focusing on the second column. The C-peptide peak refocused on the second-dimension column was eluted by an MS-compatible mobile phase and quantified by MS.
Samples injected on the first column contained 0.34 mol/L potassium phosphate. Basic phosphates slowly dissolves column silica, leading to column deterioration. To avoid this effect, we reconstituted samples in 50 mL/L acetonitrile containing 3 mL/L TFA, with a final pH of ϳ3. This method approach demonstrated excellent ruggedness (see below).
choice of columns
The first dimension chosen was a Jupiter C 5 column. We chose Phenomenex-brand LC columns on the basis of availability of short (length, 4-mm) guard cartridges, which had minimal effect on retention times when short analytical columns were used and could be replaced with minimal analyte retention time shift. Additional considerations were pore size; 300Å silica has a smaller surface area and thus faster analyte elution (compared with matrices with smaller pore sizes), generates lower back pressure, and can be regenerated and reequilibrated more rapidly. Although C 3 -C 5 substituted RP columns at low pH stably captured the relatively hydrophobic C-peptide, C 5 was chosen because of its increased resistance to acidic hydrolysis and potentially longer life. We made more than 1000 injections of SPE plasma extracts before replacing this column.
For the second dimension, we chose a Pursuit C 18 column, a high-resolution, fast, MS-compatible column from Varian. Because of its relatively large pore size, this column generates less backpressure than typical 100 -120 Å RP columns. It is important to keep overall backpressure of 2-dimensional methods as low as possible.
method validation SPE C-peptide recovery. The typical yield of C-peptide from plasma after SPE was 83.9% (range, 78%-89%; n ϭ 5).
Linearity. We tested initial linearity with a 12-point dilution curve. Absolute C-peptide signal area was linear over a 500-fold range (0.010 to 5 ng) on column (mean r 2 ϭ 0.9973; n ϭ 3 experiments; Fig. 3A) . The assay was further calibrated over 6 points against the [Mϩ30] IS by serial dilutions of the IS with human plasma. The linearity was even better when C-peptide was measured in the IDA vs the [Mϩ30] IS, with an intercept not significantly different from zero (r 2 ϭ 0.9995; y ϭ 0.99x ϩ 0.002; Fig. 3B ).
Precision. The precision data are summarized in Table 2 and Table 1 of the Data Supplement that accompanies the online version of this article at http://www.clinchem. org/content/vol52/issue5/. We added known amounts of [Mϩ30] human Cpeptide to human plasma to achieve final concentrations of 0.8 to 4.1 g/L, consistent with the range of concentrations in fasting and stimulated plasma samples (see physiologic data below), and measured the concentrations by LC/MS. As shown in Table 1 of the online Data Supplement, recoveries ranged from 99% to 102% of expected. The relative and absolute errors demonstrated no concentration bias, with the former being Ͻ3%.
To evaluate precision and reproducibility, we prepared quality-control samples composed of human C-peptide in plasma and synthetic [Mϩ30] isotope-labeled C-peptide (9.8 g/L) at mean (SD) concentrations of 0.9 (0.01), 3.3 (0.1), and 14.9 (0.1) g/L. We measured 5 sets of 6 replicates over 5-10 days on the API 4000, with 0.2-2.4 ng of endogenous C-peptide injected on the column. The assay was highly reproducible with both the inter-and intraday CVs Ͻ2% (Table 2) . Additional reproducibility data generated on the API365 mass spectrometer over a 3-month period with C-peptide and 15 N-labeled C-peptide tracer quality-control standards dissolved in an albumin buffer gave interday CVs of 3.5% and 2.7%. These measurements extended from February to May, during which 9°C seasonal temperature fluctuations occurred in the laboratory. We have previously observed that temperature fluctuations can be an important source of measurement instability if not properly controlled.
The limit of quantification (LOQ) of our LC/MS assay on the API4000 was 0.16 g/L (54 pmol/L), equivalent to 10 pg (3 fmole) on column, which we determined by use of the IUPAC definition of 10 times the SD of the background noise of a C-peptide-negative plasma matrix divided by the slope of the calibration graph (20 ) . At this concentration, the imprecision was well within 10% of expected. The limit of detection and the true lower LOQ were likely even lower given the high S/N ratio (1 pg on column yielded a S/N ratio of 8), the possibility of injecting on column the equivalent of Ͼ60 L of plasma, Clinical Chemistry 52, No. 5, 2006 and the extremely low between-sample carryover (Ͻ0.1%). An example of a plasma sample with a Cpeptide concentration near the LOQ is shown in Fig. 3C .
[Mϩ30] C-peptide added to healthy human plasma at a nominal concentration of 0.17 g/L, extracted, and measured by 2D LC/MS gave a S/N ratio of ϳ50 with minimal background.
comparison of ria vs ida by ms
We used RIA and IDA to simultaneously analyze 190 plasma samples from 8 separate human physiology studies. Plasma C-peptide concentrations varied over a 20-fold range, from 0.4 -1 g/L basally to ϳ8 g/L after nutrient stimulation. The full data set is presented in Fig. 1A of the online Data Supplement, with the regression line and the 95% prediction intervals. The results between methods were highly correlated (r ϭ 0.964). The results obtained by immunoassay were ϳ70% higher than those obtained by IDA. The regression equation (y ϭ 1.66x Ϫ 0.41) had an intercept that was not significantly different from zero.
Although the absolute difference between IDA and RIA values was larger at higher C-peptide concentrations, the relative differences were independent of concentration (see Fig. 1B of the online Data Supplement). In addition, we used the regression equation to calculate the theoretical C-peptide concentrations for RIA from the IDA data. A plot of the relative residuals between the actual and theoretical RIA values was approximately symmetrical around zero at all concentrations, indicating that the difference was not concentration dependent (see Fig. 1C of the online Data Supplement).
stimulation of endogenous insulin secretion
C-Peptide concentrations measured by 2D LC/MS IDA in the basal state as well as in response to hyperglycemic stimulation are shown in Fig. 4 . Basal concentrations were constant during the fasting state and increased in a physiologic fashion in response to intravenous glucose. Two peaks were observed, an initial sharp peak 2-5 min after initiation of hyperglycemia, and a broad second peak thereafter, representing first-and second-phase insulin secretion, respectively (2-4 ) . The C-peptide pattern is consistent with normal C-peptide secretion rates (2-4 ).
Discussion
C-Peptide has been used as a plasma marker of intact insulin secretory capacity and to differentiate true insulin deficiency characteristic of type 1 diabetes from the relative insulin insufficiency seen in type 2 diabetes. Measurement of C-peptide secretion and clearance is also used to characterize dysfunctional insulin secretion in the prediabetic state (21, 22 ) .
IDAs are used to measure metabolites (17 ) , small drug molecules in biological fluids (23, 24 ) , and large complex molecules such as peptide hormones (6, 7, (13) (14) (15) (16) 18 ) . For reported C-peptide assays, the lowest amount measured was 30 fmole on column, which was obtained via initial immunoprecipitation/SPE followed by off-line RP chromatography and direct MS detection (7 ); the detection limit was also 30 fmole for ultrafiltration followed by RP LC/tandem MS (6 ). Our method, with a detection limit Ͻ300 amole, has a limit of detection 100-fold lower than those of immunoassays for C-peptide (0 -60 pmol/L for C-peptide RIA and ELISA; Linco Research; data on file), taking into account that maximum plasma volumes for such assays are fixed.
Although this sensitivity gain is partly attributable to advances associated with our API 4000, the most important variable is the decrease in background attributable to efficient 2-dimensional chromatography (Fig. 2 and Fig.  3C ) (18 ) . Even small amounts of residual cations from plasma or TFA from the first-dimension chromatography can cause significant ion suppression (18 ) . Tandem MS can differentiate C-peptide from contaminants (6 ), but its low fragmentation efficiency can lead to a substantial loss in signal (60-fold decrease) (18 ) . The use of 2D LC/MS reduces matrix effects and increases overall assay sensitivity. Initial prepurification may also lead to analyte loss, with recovery of 60% for ultrafiltration (6 ) and Ն80% for SPE [Ref. (7 ) and this report]. Our SPE procedure [modified from Ref. (7 )] enabled simple and rapid sample preparation while preserving high recovery. Other advantages of our approach were as follows: (a) the use of only 0.3 mL of plasma avoided the necessity of diluting larger volumes of plasma; (b) use of 50 mL/L acetonitrile without TFA for the sample dilution, loading, and initial wash steps avoided problems caused by plasma treatment at acidic pH; (c) off-line purification by Sep-Pak Plus is more convenient than with the classic Sep-Pak because Sep-Pak Plus cartridges have smaller dead volume and are less expensive; (d) use of a 1-mL pipette for sample loading and the first wash step eliminated syringe use and reduced preparation costs and the probability of clogging the SPE inlet filter; (e) elution of bound peptide with 350 mL/L acetonitrile in 25 mmol/L potassium phosphate (pH 8) increased C-peptide purity in the eluted (collected) fraction; (f) this method requires Ͻ4 min per sample, provides sufficient material for quadruplicate injections, and generates cleaner samples, increasing column lifetime (and reducing cost per sample).
Strong adsorption of C-peptide (and insulin) to the surface of plastic and glass vials, which increases with increasing C-peptide purity, can decrease recovery (18 ) . Thus, the higher sample purity obtained by elution with 350 mL/L instead of 500 mL/L acetonitrile led to a decrease in C-peptide recovery after SPE (data not shown). The addition of salts to the dried SPE extract and the high final concentrations of phosphate and GuHCl prevented C-peptide binding to the polypropylene filter housing and tubes; therefore, silanol-treated vials were unnecessary (data not shown), and the use of RP columns for both dimensions of LC eliminated problems from matrix effects at high salt concentrations ( Fig. 2 and Fig.  3C ) (12, 18 ) .
Although a triple quadrupole mass spectrometer was available, we initially did not pursue sensitivity enhancement by tandem MS because we achieved highly efficient separation and eliminated matrix effects with the 2-dimensional method, with similar backgrounds for actual plasma samples and the solvent blank (Fig. 2) . We have since determined that no additional benefit would be derived from the use of tandem MS over single-quadrupole detection (unpublished data).
IDAs detect only the authentic intact analyte, and as such represent the emerging "gold standard" for analyte detection and quantification. Numerous immunoassays for C-peptide have been reported that use single as well as sandwich antibody methods [reviewed in Refs. (8, 10 ) ]. Although all commercially available assays have been standardized against WHO international reference preparation 84/510, there is a surprisingly large degree of inconsistency in results for different assays (7, 9 ) , and we observed mean measured plasma concentrations that were 60% higher by RIA than by 2D LC/MS (see Fig. 1 in the online Data Supplement).
The strong correlation of our 2D LC/MS assay with RIA and the physiologic response of plasma C-peptide to stimulated insulin secretion demonstrate the suitability of our method, but MS and immunoassay methods differ, with values being higher for the latter in all cases. Our assay, which detects C-peptide at lower concentrations than an established immunoassay method, is consistent with the specificity of IDA for detecting only intact C-peptide. Although the RIA used had minimal sensitivity to intact proinsulin, other cross-reacting species might exist. A C-peptide with 2 basic amino acids at the COOH terminus may result from incomplete cleavage of proinsulin molecules (5 ) . The C-peptide LysArg species has been found to make up 0%-10% of C-peptide concentrations in random samples (7 ) . C-Peptide cleavage products are another likely source of C-peptide immunoreactivity (25, 26 ) , and proinsulin cleavage products can account for up to 30% of total insulin in circulation (7, 27 ) . It is currently unknown whether clinical immunoassays detect these species, although one commercial immunoassay clearly does (25 ) .
C-Peptide catabolic products with an increased halflife relative to intact C-peptide could contribute to Cpeptide immunoreactivity. Our results concerning C-peptide production in response to glucose stimulation are consistent with our assay monitoring only the processing of full proinsulin to C-peptide, but more data are required to elucidate C-peptide metabolism and the relationship between immunoreactive species and intact C-peptide detected by IDA.
In summary, we have developed a rugged, cost-effective 2D LC/MS method for measurement of C-peptide in human plasma that has a detection limit 100-fold lower than those of any previously reported IDAs and is comparable in sensitivity to established immunoassays. Results correlated highly with an established immunoassay for C-peptide across the physiologic range. This method provides a new tool to study the production and clearance rates of endogenously produced peptides and hormones implicated in many disease states, including obesity and diabetes. With continued improvements in peptide labeling and MS instrumentation, IDA could provide new insights into the in vivo metabolism of secreted proteins.
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